Literature DB >> 9346454

Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions.

P W Jungnickel1, P A Maloley, E L Vander Tuin, T E Peddicord, J R Campbell.   

Abstract

OBJECTIVE: To compare the effects of pretreatment with two aspirin regimens and placebo on niacin-induced cutaneous reactions.
DESIGN: Randomized, double-blind, placebo-controlled, crossover study.
SETTING: Internal medicine clinic in an academic health center. PARTICIPANTS: Forty-two healthy subjects (22 males and 20 females) between the ages of 35 and 65 (mean age 44.2 years) were recruited and completed the study. Subjects received aspirin 325 mg, aspirin 650 mg, and placebo for 4 consecutive days, and on the fourth day also ingested 500 mg of immediate-release niacin 30 minutes after taking aspirin or placebo. They reported the intensity of flushing, headache, pruritus, tingling, and warmth on a 10-cm visual analogue scale. Reactions were evaluated at time 0 (before the niacin dose), and at 15, 30, 60, and 120 minutes following the niacin dose. Cutaneous reactions were compared at each evaluation time and scored by two other methods. The peak intensity was the highest score recorded at any of the four evaluation times after niacin administration. An intensity-time factor was calculated by totaling the scores of each of the four evaluation times. MEASUREMENT AND MAIN
RESULTS: The symptom scores for flushing, itching, tingling, and warmth were all significantly reduced by both aspirin regimens (p < .05 in all cases), although there were no significant differences between the 325-mg and 650-mg doses. The results were similar for each scoring method.
CONCLUSIONS: An aspirin regimen of 325 mg is effective in suppressing niacin-induced cutaneous reactions. Increasing the dose to 650 mg does not provide additional benefit.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9346454      PMCID: PMC1497169          DOI: 10.1046/j.1525-1497.1997.07118.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  11 in total

Review 1.  Niacin for primary and secondary prevention of cardiovascular events.

Authors:  Stefan Schandelmaier; Matthias Briel; Ramon Saccilotto; Kelechi K Olu; Armon Arpagaus; Lars G Hemkens; Alain J Nordmann
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

Review 2.  A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

Review 3.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

4.  Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

Authors:  Kang Cheng; Tsuei-Ju Wu; Kenneth K Wu; Claudio Sturino; Kathleen Metters; Keith Gottesdiener; Samuel D Wright; Zhaoyin Wang; Gary O'Neill; Eseng Lai; M Gerard Waters
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

Review 5.  Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.

Authors:  Klaus G Parhofer
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

6.  The flavonoid luteolin inhibits niacin-induced flush.

Authors:  D Papaliodis; W Boucher; D Kempuraj; T C Theoharides
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 7.  Niacin, an old drug with a new twist.

Authors:  Wen-Liang Song; Garret A FitzGerald
Journal:  J Lipid Res       Date:  2013-08-15       Impact factor: 5.922

Review 8.  The mechanism and mitigation of niacin-induced flushing.

Authors:  V S Kamanna; S H Ganji; M L Kashyap
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

Review 9.  Mechanisms of flushing due to niacin and abolition of these effects.

Authors:  Aditya Sood; Rohit Arora
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-11       Impact factor: 3.738

10.  The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903].

Authors:  Edward Mills; Jonathan Prousky; Gannady Raskin; Joel Gagnier; Beth Rachlis; Victor M Montori; David Juurlink
Journal:  BMC Clin Pharmacol       Date:  2003-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.